CA1153334A - System for externally treating human blood - Google Patents
System for externally treating human bloodInfo
- Publication number
- CA1153334A CA1153334A CA000366516A CA366516A CA1153334A CA 1153334 A CA1153334 A CA 1153334A CA 000366516 A CA000366516 A CA 000366516A CA 366516 A CA366516 A CA 366516A CA 1153334 A CA1153334 A CA 1153334A
- Authority
- CA
- Canada
- Prior art keywords
- blood
- radiation
- psoralen
- subject
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3616—Batch-type treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
- A61M1/3686—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents by removing photoactive agents after irradiation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/03—Heart-lung
Abstract
Abstract A method and system are disclosed for externally treating human blood, with the objective of reducing the func-tioning lymphocyte population in the blood system of a human subject. According to the method, blood is withdrawn from the subject and passed through an ultraviolet radiation field in the presence of from about 1 nanogram to 100 micrograms per ml of blood, of a dissolved psoralen capable of forming photoadducts with DNA, to thereby effect covalent bonding between the psoralen and the nucleic acid of the lymphocytes, thereby altering the said nucleic acid and inhibiting the metabolic processes of the lymphocytes; and thereupon returning the irradiated blood to the subject. The withdrawn blood may be formed into an extracorporeal stream and flowed through a treatment station whereat the irradia-tion is effected, as for example by exposure to W energy in the wave length range of from about 3200 to 4000 Angstroms; and such flow process may be conducted on a continuous basis. If desired, at least portions of the treated blood may then be separated, as for example by a continuous centrifuge, before re-turning the remaining diverted blood to the subject.
Description
llS33;~4 A SYSTEM FOR EXTERNALLY
TREATING HUMAN BLOOD __ This invention relates generally to a system for medical treatment of the human body, and more specifically relates to a system usable in treating the blood supply of a human subject for the purpose of reducing the 5 functioning lymphocyte population in the blood supply of such subject.
In a number of highly significant human diseases, in-cluding certain forms of leukemia, the population of certain types of leucocytes, including especially lymphocytes, in-creases inordinately in comparison to the other populations ofnucleated cells in normal blood. While the excessive population of such lymphocytes represents a result of, rather than the underlying cause of the disease, the excessive lymphocyte popula-tion brings direct adverse effects to the patient if steps are not taken to reduce same. Complications thus rapidly develop which impair function of bodily organs, and eventually a life-threatening situation is presented.
' .~
. .
~i533~4 It should also be appreciated that excessive increase in the lymphocyte population of the blood supply can occur in other human maladies, in addition to lymphocytic leukemias.
Thus, for example, such results can obtain in consequence of severe allergic reactions to administered agents, including drugs or the like, or in many other lymphocyte-mediated diseases.
In addition to the development over the years of phar-maceutical agents and the like, which may nonspecifically reduce the lymphocyte population, e.g. by altering the underlying pro-duction rate of same, various techniques have from time to time : been used in an effort to directly attack the problem, as for , example by mechanically removing such lymphocytes from the blood supply. It is thus known, for example, to pass the blood supply through a continuous centrifuge, whereat one seeks to selectively remove lymphocytes to reduce the population of thelatter in the thereby processed blood supply. In general, how-ever, this method tends to be very inefficient, in part because the density differences between the blood fractions including the undesired lymphocytes and fractions which include desired blood components, is insufficient to assure that high percen-: tages of the former are removed while retaining high proportions of the latter.
It is also well-known to treat diseases such as leukemia with high energy electromagnetic radiation, including 25 in the X-ray region. While such treatment is often directed at ~'' ~.,, : :
':, .
llS33~4 internal bodily organs whereat the blood cells are being generated, it has also been known to irradiate the blood supply with x-radiation at a point external to the body (the blood having first been withdrawn), whereby the radiation is not rendered directly incident on the body or internal organs of same. This method, while powerful, is indiscrimate, in that the intensely disruptive energy, in addition to destroy-ing undesirable cells, disables or destroys components of the blood which are desired to be retained in vital status.
For many years, it has been known that certain ~; heterocyclic furocoumarins possess photoactive properties that render same useful in the treatment of certain human diseases.
A noteworthy example of this occurs in certain recently reported methods for treatment of psoriasis.
The photoactive compounds referred to are prim~rily m~ers of a group of coumarin derivatives which are commonly referred to as "psoralens", the basic member of which is the (photoactive) compound psoralen, having the structure:
; .:
5;
~ 20 (l) 1~ ~ X
'.` '' The remaining compounds of interest for this invention '' .
. .
.. ' .
~15~33~
are (a) derivatives of psoralen, i.e. of structure ~1) and (b) other WA responsive agents (as will be discussed in greater detail hereinbelow). In accordance, however, with accepted terminology in the nomenclature of the pertinent chemical art, the phrase "psoralen" or "a psoralen" will be used at places in this specification to refer to certain derivatives of structure (1) which include "psoralen" in their accepted name, such as 8-methoxypsoralen, S-methoxypsoralen, etc.
In an article appearing in the New England Journal of Medicine, Volume 291, No. 23 for December 5, 1974, John A.
Parrish, M.D. et al, thus report a method involving oral adminis-tration of 8-methoxypsoralen (8-MOP) to a patient who is there-after treated by exposure to a high intensity long-wavelength ultraviolet light source, i.e. to a source of ultraviolet radia-tion in the WA wavelength region, and preferably in the wave-length range between about 3200 and 4000 Angstroms, with a peak emission at about 3650 Angstroms. The highly successful treat-....
ment is deemed to be effective by interrupting the disease pro-cess in psoraisis, a disorder characterized by an accelerated cell cycle and rate of DNA synthesis. The treatment acts to inhibit DNA synthesis by formation of C-4 cyclo-addition products between the pyrimidine bases of the nuclei acids and psoralen molecule. Since the 5, 6 double bond of the pyrimidine can photo-react with the psoralen molecule at either the 3, 4 double bond of the pyrone ring or at the 4', 5' double bond of the furan ring, :.
'.
"', ';
. ~
"; ' ~
... .. .
llS33;34 two types of photoadducts are possible. In consequence forma-tion of photo-induced DNA cross-links is enabled.
In this sequence of treatment thus employed in the treatment of psoriasis, it has been common to place the patient following administration of the psoralen, in a light box or other environment whereat the high intensity illumination is effected. It has come to the attention of investigators that a side effect resulting from the cited treatment, can occasionally be the destruction of certain nucleated blood cells. Investiga-tion appears to establish that such resultsobtain because the inci-dent W radiation has sufficient penetrating power, to induce some bonding between the psoralen introduced into the bloodstream and the nucleic acid of the nucleated blood cells such as the lympho-; cytes. In consequence the metabolic processes of such modified ; 15 lymphocytes are detrimentally affected, eventually leading to the ~A inactivation and ultimate destruction of same. This type of phenomenom has been studied in vitro, and among other places, is reported in an article by G. Lischka et al appearing in Archives for Dermatological Research, 259, 293-298 (1977). of interest i for present purposes is that the reported phenomenom is regarded as an undesirable side effect, which is incident to the bene-ficial results otherwise achieved during treatment of psoriasis.
Summary o Invention , Now, in accordance with the present invention, a method and system has been found which enables safe and effective ,'' ~,;
. .
6 llS33~
reduction of the functioning lymphocyte population in the blood supply of a human subject. According to the system of the invention, means are provided for irradiating blood requiring such treatment externally of the patient. This 5 procedure is accomplished with UVA radiation in a preferred wavelength range of from about 3200 to 4000 Angstroms, in the presence of from about 1 nanogram to 100 microgram per ml of blood of a dissolved psoralen of the type capable of forming photoadducts with DNA, to thereby effect covalent bonding between the psoralen 10 and the nucleic acid of the lymphocytes present in the blood.
The said nucleic acid is thereby altered to inhibit the metabolic processes of the said lymphocytes, after which the irradiated blood is returned to the human subject.
The withdrawn blood can be treatèd in batch, but 15 preferably is formed into an extracorporeal stream and passed :~ through a treatment station whereat the irradiation is effected.
~i Such treatment station may take the form of an extended flattened , tubular passageway, the walls of which are substantially trans-, parent to the incident long-wave W energy (WA) used to activate 20 the psoralen. Typical radiation doses range from about 0.1 to 100 joules per cm2 of blood surface where the process is carried out on a continuous or discontinuous basis, and typical flow rates through the irradiation station can be in the range of ~, from about 10 to 75 ml/min.
. . .
; 25 Following treatment, the entire batch, or irradiated , ,:, flow of diverted blood, can be returned to the patient with all '~
.
.`.i. .
.. ; .
"
....
..
;,.
., ' .~ ~
, . .
`. ~15~ g ` blood components intact. The lymphocytes, however, by virtue of the treatment, have been so altered that their metabolic functioning is rapidly impaired, and especially the ability of same to divide, in conse~uence of which destruction of the impaired lymphocytes rapidly occurs. Moreover, the impair-ment and destruction tends to be selective in certain diseases such as leukemia, to the cells most sought to be reduced, by virtue of the fact that it is such cells which are undergoing the most intense metabolic activities to begin with, whereby they ; 10 are the cells most subject to disablement by their present process.
A preferred psoralen for use in the process of the :
present invention is 8-methyoxpsoralen (8-MOP, also known as methoxsalen). Other photoactive psoralens useful in practice of the present invention include psoralen itself, i.e. structure (1), and 4, 5l, 8-trimethylpsoralen. Less preferred, but still useful photoactive psoralens for use in the invention include 5-methoxypsoralen, 4-methylpsoralen, 4,4-dimethylpsoralen, 4, 5'-dimethylpsoralen, and 4', 8-dimethylpsoralen.
Further discussion of these photoactive psoralens may be found in the tutorial article entitled Photobiology and Photochemistry of Furocoumarins (Psoralens) by M.A. Pathak et al, . _ which article appears as Chapter 22 of the work Sunlight and Man, edited by Thomas B. Fitzpatrick et al, University of Tokyo Press (1974). This article observes (which is appropriate for present :`
' ' ',',-`
,: , , i ; '~
": .
.
.: ' .
'~
~J 5~4 purposes) that the most effective photoactive psoralens include the compound psoralen proper, i.e. structure (l), and derivatives of structure (l) wherein methyl or methoxy groups are substituted at one or more of the 4, 4', 5' and 8 positions, as for example in the aforementioned 8-MOP, which has the structure:
TREATING HUMAN BLOOD __ This invention relates generally to a system for medical treatment of the human body, and more specifically relates to a system usable in treating the blood supply of a human subject for the purpose of reducing the 5 functioning lymphocyte population in the blood supply of such subject.
In a number of highly significant human diseases, in-cluding certain forms of leukemia, the population of certain types of leucocytes, including especially lymphocytes, in-creases inordinately in comparison to the other populations ofnucleated cells in normal blood. While the excessive population of such lymphocytes represents a result of, rather than the underlying cause of the disease, the excessive lymphocyte popula-tion brings direct adverse effects to the patient if steps are not taken to reduce same. Complications thus rapidly develop which impair function of bodily organs, and eventually a life-threatening situation is presented.
' .~
. .
~i533~4 It should also be appreciated that excessive increase in the lymphocyte population of the blood supply can occur in other human maladies, in addition to lymphocytic leukemias.
Thus, for example, such results can obtain in consequence of severe allergic reactions to administered agents, including drugs or the like, or in many other lymphocyte-mediated diseases.
In addition to the development over the years of phar-maceutical agents and the like, which may nonspecifically reduce the lymphocyte population, e.g. by altering the underlying pro-duction rate of same, various techniques have from time to time : been used in an effort to directly attack the problem, as for , example by mechanically removing such lymphocytes from the blood supply. It is thus known, for example, to pass the blood supply through a continuous centrifuge, whereat one seeks to selectively remove lymphocytes to reduce the population of thelatter in the thereby processed blood supply. In general, how-ever, this method tends to be very inefficient, in part because the density differences between the blood fractions including the undesired lymphocytes and fractions which include desired blood components, is insufficient to assure that high percen-: tages of the former are removed while retaining high proportions of the latter.
It is also well-known to treat diseases such as leukemia with high energy electromagnetic radiation, including 25 in the X-ray region. While such treatment is often directed at ~'' ~.,, : :
':, .
llS33~4 internal bodily organs whereat the blood cells are being generated, it has also been known to irradiate the blood supply with x-radiation at a point external to the body (the blood having first been withdrawn), whereby the radiation is not rendered directly incident on the body or internal organs of same. This method, while powerful, is indiscrimate, in that the intensely disruptive energy, in addition to destroy-ing undesirable cells, disables or destroys components of the blood which are desired to be retained in vital status.
For many years, it has been known that certain ~; heterocyclic furocoumarins possess photoactive properties that render same useful in the treatment of certain human diseases.
A noteworthy example of this occurs in certain recently reported methods for treatment of psoriasis.
The photoactive compounds referred to are prim~rily m~ers of a group of coumarin derivatives which are commonly referred to as "psoralens", the basic member of which is the (photoactive) compound psoralen, having the structure:
; .:
5;
~ 20 (l) 1~ ~ X
'.` '' The remaining compounds of interest for this invention '' .
. .
.. ' .
~15~33~
are (a) derivatives of psoralen, i.e. of structure ~1) and (b) other WA responsive agents (as will be discussed in greater detail hereinbelow). In accordance, however, with accepted terminology in the nomenclature of the pertinent chemical art, the phrase "psoralen" or "a psoralen" will be used at places in this specification to refer to certain derivatives of structure (1) which include "psoralen" in their accepted name, such as 8-methoxypsoralen, S-methoxypsoralen, etc.
In an article appearing in the New England Journal of Medicine, Volume 291, No. 23 for December 5, 1974, John A.
Parrish, M.D. et al, thus report a method involving oral adminis-tration of 8-methoxypsoralen (8-MOP) to a patient who is there-after treated by exposure to a high intensity long-wavelength ultraviolet light source, i.e. to a source of ultraviolet radia-tion in the WA wavelength region, and preferably in the wave-length range between about 3200 and 4000 Angstroms, with a peak emission at about 3650 Angstroms. The highly successful treat-....
ment is deemed to be effective by interrupting the disease pro-cess in psoraisis, a disorder characterized by an accelerated cell cycle and rate of DNA synthesis. The treatment acts to inhibit DNA synthesis by formation of C-4 cyclo-addition products between the pyrimidine bases of the nuclei acids and psoralen molecule. Since the 5, 6 double bond of the pyrimidine can photo-react with the psoralen molecule at either the 3, 4 double bond of the pyrone ring or at the 4', 5' double bond of the furan ring, :.
'.
"', ';
. ~
"; ' ~
... .. .
llS33;34 two types of photoadducts are possible. In consequence forma-tion of photo-induced DNA cross-links is enabled.
In this sequence of treatment thus employed in the treatment of psoriasis, it has been common to place the patient following administration of the psoralen, in a light box or other environment whereat the high intensity illumination is effected. It has come to the attention of investigators that a side effect resulting from the cited treatment, can occasionally be the destruction of certain nucleated blood cells. Investiga-tion appears to establish that such resultsobtain because the inci-dent W radiation has sufficient penetrating power, to induce some bonding between the psoralen introduced into the bloodstream and the nucleic acid of the nucleated blood cells such as the lympho-; cytes. In consequence the metabolic processes of such modified ; 15 lymphocytes are detrimentally affected, eventually leading to the ~A inactivation and ultimate destruction of same. This type of phenomenom has been studied in vitro, and among other places, is reported in an article by G. Lischka et al appearing in Archives for Dermatological Research, 259, 293-298 (1977). of interest i for present purposes is that the reported phenomenom is regarded as an undesirable side effect, which is incident to the bene-ficial results otherwise achieved during treatment of psoriasis.
Summary o Invention , Now, in accordance with the present invention, a method and system has been found which enables safe and effective ,'' ~,;
. .
6 llS33~
reduction of the functioning lymphocyte population in the blood supply of a human subject. According to the system of the invention, means are provided for irradiating blood requiring such treatment externally of the patient. This 5 procedure is accomplished with UVA radiation in a preferred wavelength range of from about 3200 to 4000 Angstroms, in the presence of from about 1 nanogram to 100 microgram per ml of blood of a dissolved psoralen of the type capable of forming photoadducts with DNA, to thereby effect covalent bonding between the psoralen 10 and the nucleic acid of the lymphocytes present in the blood.
The said nucleic acid is thereby altered to inhibit the metabolic processes of the said lymphocytes, after which the irradiated blood is returned to the human subject.
The withdrawn blood can be treatèd in batch, but 15 preferably is formed into an extracorporeal stream and passed :~ through a treatment station whereat the irradiation is effected.
~i Such treatment station may take the form of an extended flattened , tubular passageway, the walls of which are substantially trans-, parent to the incident long-wave W energy (WA) used to activate 20 the psoralen. Typical radiation doses range from about 0.1 to 100 joules per cm2 of blood surface where the process is carried out on a continuous or discontinuous basis, and typical flow rates through the irradiation station can be in the range of ~, from about 10 to 75 ml/min.
. . .
; 25 Following treatment, the entire batch, or irradiated , ,:, flow of diverted blood, can be returned to the patient with all '~
.
.`.i. .
.. ; .
"
....
..
;,.
., ' .~ ~
, . .
`. ~15~ g ` blood components intact. The lymphocytes, however, by virtue of the treatment, have been so altered that their metabolic functioning is rapidly impaired, and especially the ability of same to divide, in conse~uence of which destruction of the impaired lymphocytes rapidly occurs. Moreover, the impair-ment and destruction tends to be selective in certain diseases such as leukemia, to the cells most sought to be reduced, by virtue of the fact that it is such cells which are undergoing the most intense metabolic activities to begin with, whereby they ; 10 are the cells most subject to disablement by their present process.
A preferred psoralen for use in the process of the :
present invention is 8-methyoxpsoralen (8-MOP, also known as methoxsalen). Other photoactive psoralens useful in practice of the present invention include psoralen itself, i.e. structure (1), and 4, 5l, 8-trimethylpsoralen. Less preferred, but still useful photoactive psoralens for use in the invention include 5-methoxypsoralen, 4-methylpsoralen, 4,4-dimethylpsoralen, 4, 5'-dimethylpsoralen, and 4', 8-dimethylpsoralen.
Further discussion of these photoactive psoralens may be found in the tutorial article entitled Photobiology and Photochemistry of Furocoumarins (Psoralens) by M.A. Pathak et al, . _ which article appears as Chapter 22 of the work Sunlight and Man, edited by Thomas B. Fitzpatrick et al, University of Tokyo Press (1974). This article observes (which is appropriate for present :`
' ' ',',-`
,: , , i ; '~
": .
.
.: ' .
'~
~J 5~4 purposes) that the most effective photoactive psoralens include the compound psoralen proper, i.e. structure (l), and derivatives of structure (l) wherein methyl or methoxy groups are substituted at one or more of the 4, 4', 5' and 8 positions, as for example in the aforementioned 8-MOP, which has the structure:
(2) ~ ~ `
:~ OCH3 and 4, 5', 8-trimethylpsoralen, which has the structure:
~: 15 . ~
CH3 ~ 0 ~ 0 ~ 0 : CH3 .. As aforementioned, the reactive sites of the nucleic : acids are considered to be the pyrimidine bases, and it is believed that the photoinduced reaction of the present invention . involves the activated psoralen and one or more of the , 25 pyrimidine bases normally present in nucleic acids, such as ;.~, . .
~`
..
~i ; .~
.,,,~ .
.
.: , .
~lS.~3~4 thymine, cytosine, uracil or so forth. A C4 cyclo-addition takes place; the pyrimidine bases always react with their 5, 6 double bond, while the psoralens can react with either their 3, 4 double bond or with their 4', 5' double bond. In consequence two S types of photo-adducts can be obtained. This ability to bond ; at two regions of the linear psoralen structure enables the said structure upon photo-activation to link to one pyrimidine base, or to two pyrimidine bases which engage both of the reactive double bonds of the psoralen structure. Where this double linking occurs, cross-linking can be effected between the two strands of DNA, which is particularly effective in inhibiting the metabolic ; functions of the associated nucleated cells, such as the lympho-cytes.-Brief Description of Drawings The invention is diagrammatically illustrated, by way of example, in the drawings appended hereto, in which:
Fig. 1 is a schematic flow diagram illustrating a preferred embodiment of a system operating in accordance with the present invention;
Fig. 2 is a schematic elevational view of the irradia-tion station portion of the Fig. 1 system;
Fig. 3 is a plan view, schematic in nature, of one embodiment of the irradiation station of Fig. 2; and Figs. 4 and 5 are cross-sectional views, taken along the lines 4-4 and 5-5 of ~ig. 3, and illustrate the configura-'' . . .
. .
.
;,',"
.
,,; ~
10 .
~15~?,,3:~4 tions of the flow passageway and the output passage for the Fig. 3 device.
Description of Preferred Embodiment In Fig. 1 herein a schematic diagram appears of a system 10 in accordance with the present invention. Except for the irradiation station, the bulk of the components of system 10 are per se conventional and known in the art; and hence it is not deemed appropriate or necessary to vastly detail same.
As indicated in the Figure, blood may initially be withdrawn from the human subject, as at 12. Typically the ` blood is withdrawn via a donor needle, which may e.g. be emplaced at the right antecubital vein. In the showing of Fig. 1, it is assumed that the processing of blood pursuant to the invention is conducted on a continuous basis, i.e. for purposes of the present discussion the flow may be regarded as continuous from withdrawal at 12, to final return of the blood to the subject at 14. Such return 14 is typically effected via a recipient needle positioned in the left antecubital vein. Where the flow is indeed continuous in this manner, a typical blood flow -20 1 utilizable in practice of the invention is in range of from about j 10 to 75 ml/min, with a more preferred range being from about 40 to 50 ml/min. The indicated flow rates are effected by means of a pump 16, which is positioned in the extracorporeal blood flow - stream generally indicated at 18, and may comprise one of numerous , 25 types of pumps used for blood flow treatment purposes, including .
.~ ~
lS~4 such pumps as those available from Haemonetics Corp. under Model Designation 30.
As is known in the pertinent medical art, anti-coagu-lants are preferably injected into the extracorporeal blood flow stream at 20, i.e. close to the point of blood withdrawal.
Such anti-coagulants can comprise solutions of acid citrate dextrose and/or of heparin, or of other known compositions useful - for this purpose.
An occluded vein sensor 22 is preferably provided in stream 18 for purposes, as known in the art. Such sensor basically comprises a reservoir or buffer volume, the object of which is to prevent or inhibit generation or continued existence of bubbles in the blood flow stream.
Pursuant to a preferred mode of practicing the present invention, the photoactive psoralen is preferably added to the blood of the human subject external to such subject; and thus ,~ as sho~n in the system 10 of Fig. 1, may be provided to the flowing blood downstream of pump 16, and just upstream of where the blood enters the irradiation station 24.
As has been discussed under the "Summary of Invention", the preferred psoralen for use in the process of the invention is 8-methoxypsoralen (8-MOP). As also discussed, other photoactive ; psoralens as previously described, are also utilizable in the method of the invention. The basic technique used in introducing the psoralen, is to dissolve same in an isotonic solution, which ~, :- .
.
'' .
.
l~S;~
thereafter is directly injected into the flowing blood streams, as at 26. The psoralen is injected at a rate in comparison to the blood flow rate, as to achieve a concentration in the blood thereafter passed to irradiation station 24, of from about 1 nano-gram to 100 micrograms of dissolved psoralen per ml of blood.
In the foregoing connection it should be appreciated that the primary objective of the operations thus far described - is one of achieving the desired dissolved concentration of the photoactive psoralen prior to introduction of the blood to ; 10 the irradiation station. In accordance with a further aspect of the invention, it will therefore be appreciated that the said photoactive compound need not necessarily be directly introduced by injection into the extracorporeal blood stream 18 flowing in Fig. 1. RaLher, it is also acceptable to achieve the desired psoralen concentration levels by orally or otherwise administer-ing the compound directly to the patient.
,~ Indeed, in those instances of the prior art which have . .~.
been heretofore discussed, wherein 8-MOP has been utilized in treatment of psoriasis, it has been usual for the psoralen to ~": . .
be orally administered. Where, pursuant to the invention, the i psoralen is thus orally administered, it can be provided in oral dosages of from about .6 to 1.0 mg per kg of body weight.
~.
The desired concentration range in the blood used for practice of the invention, is then achieved in about two hours from oral administration.
'' .. ~
.
.~ ~
l~S;~3~
a However, it is preferred to introduce the psoralen to the extracorporeal stream (or to an extracorporeal batch volume) in order to achieve more exact concentration levels;
and further, to avoid or minimize possible side effects and the like, which can occur from administration of any drug directly to the body system.
At irradiation station 24, consisting of an irradiation chamber 28 and radiation source 30, the blood now carrying in solution the desired psoralen concentration, is subjected to ultraviolet radiation in the WA portion of the spectrum.
10, Such WA portion of the spectrum includes primarily wave lengths in the range from about 3200 to 4600 Angstroms. For present purposes it is preferred to use a radiation source having the bulk of its spectral components in the 3200 to 4000 Angstrom range, with peak intensities at about 3600 to 3700 Angstroms.
", 15 ,~ Such radiation passes readily through conventional clear plastic ;; tubing.
-' In Fig. 2, a schematic elevational view appears of ~; an irradiation station 24 of a type suitable for use with the ~ invention. Such station consists of a blood treatment or ;; -20 -,~ irradiation chamber 28, having an inlet 31 and an outlet 32, enabling blood flow through the chamber, and a spaced source 30 of WA
radiation. The chamber 28 can take various forms, with the principle requirement for same being that the wall 34 of same opposed to source 30, be substantially transparent to the incident WA radiation. The said chamber (or at least wall 34) :,., .~
,i,,, ' ' , ~ , . . :
:
~1S,~ 3~
can therefore typically be comprised of various substantially WA-transparent plastics, as are commonly used in tubing con-structed for administration of standard intrav~nous solutions, such as polyvinyl chloride and the like.
In one embodiment of chamber 28, the said device can comprise a simple envelope, i.e., the central void 36 is substantially of thin rectangular cross-section. Where, how-..;
ever, the blood is to be treated as preferred, on a continuous basis, superior flow characteristics and better control of the exposure time can be achieved where blood treatment chamber 28 has a configuration as shown in Figs. 3, 4 and 5. In this instance a tubular coil 38, which in cross-section (Fig. 5) is ,~~ flattened to a very elongated elipse, is fixedly maintained in or upon a support plate 40. The blood flow inlet 30 to the coil is of circular cross section, and in terms of Fig. l is at a .....
point downstream of pump 16. The feed-in for the psoralen com-pound is schematically depicted at 26. The highly flattened ~; cross-section of the coil enables good flow for the blood passing through the coil, but more importantly, enables good exposure of the flowing blood to the incident WA radiation. The ; outlet 32 is again returned to a circular cross-section.
' WA source 30 may comprise one or a plurality of side-by-side or otherwise arranged WA light sources 41, each of which may be backed by a reflector 42. The ~VA sources can ~ 25 comprise commercially available lamps, numerous types of which '~
~ . .
. ~
.~ ~
15.
~l~s;~3~
:`
are known in the art.
By way of example, source 30 can comprise a single 1000 watt Hg lamp of the type available from Oriel Corporation `~ of Stamford, Connecticut, under Model designation 6287. When used with appropriate filters this source provides a good relatively contiuous spectrum of high intensity radiation between 3200 and 4000 Angstroms, with a peak emission at about 3650 Angstroms. The said lamp with a suitable reflector can be positioned approximately 5 to 30 cm from chamber 28.
With the flow rates utilized in accordance with one aspect of the invention, such a source will provide absorbed energy in the flowing blood within the range of interest for practicing the method of the invention.
The blood flow from irradiation station 24 proceeding as shown in Fig. 1 via outlet 32, can be directly returned to -:, the subject at 14. Under these circumstances, the modified lymphocyes, i.e. wherein bonding of nucleic acid to the . ., ~: photo-activated psoralen compounds has been effected, are impaired in their metabolic processes, in consequence of which : 20 the said lymphocytes will be rapidly broken down and destroyed by normal processes occuring in the subject. Since further, and as already discussed, ~he metabolic processes in the abnormal lymphocytes associated with disease conditions are usually ~-~ accelerated, the breakdown in functioning, and the destruction of such abnormal lymphocytes, is accelerated beyond the cor-. .
. ~ t .. . ' .
16.
`;`
responding effects on rate of normal lymphocytes, thereby con-tributing to the destruction of the abnormal lymphocyte population in the blood supply of the subject.
; The burden placed upon the body's organ system, how-S ever, can be further alleviated, by utilizing in conjunction with the present system, a continuous centrifuge 44, which , device serves several functions.
It is to be noted that continuous centrifuges of the type here utilized, have been long employed in blood flow processing systems commercially available from several manu-;: acturers, including Haemonetics Corporation of`Braintree, Massachusetts, and the IBM Corporation, Medical Products Division, ~; of Monsey, New York. In the prior art systems in which such de-vices have been utilized all elements of Fig. 1 have been present, with the singularly important exception of the irradiation station ^- 24. The function of the continuous centrifuge in such prior art systems has been one of separating excess lymphocytes or other , blood components of interest. Where so used, a detriment of such system was the inefficiency of same, i.e. the centrifuging process i` 20 can at best remove about 40 to 50% of the lymphocytes, and unfor-v tunately also removes numerous components which are in fact desired to be retained.
In the system 10 of the present invention, two functions :, can be performed by the continuous centrifuge 44. One of ' 25 these, is removal of lymphocytes, as previously discussed.
''' ' '' .
.
~533;~4 Because the present invention, however, relies primarily on impairment of function of the lymphocytes to ultimately re-duce the functioning population of same, the centrifuge 44 need not be relied upon to the extent that same has been in . 5 the aforementioned prior art arrangements. From a mechanical viewpoint, this implies that one need not work as close to the specific gravity interface between the lymphocyte fraction of the blood and the desirable fractions of the blood which ....
, one seeks to retain. Thus one can avoid undue separation of those desired fractions of the whole blood.
,, .~. i The continuous centrifuge 44, may further be utilized for an additional important purpose. In particular, some or ~r~, virtually all of the blood plasma may be removed at 46 and ,,;
replaced with fresh plasma at 48. This washing technique ~ 15 enables one to effectively withdraw the excess psoralen compounds which may be presented in the blood plasma, replacing the plasma !, at 46 with psoralen-free isotonic fluid. Thus, when the blood is returned to the subject at 14, it is substantially free of any excess psoralens, i.e. other than those which have combined -20 with the nucleic acid components of the lymphocytes in the manner desired.
It should also be reemphasized that while the preferred mode of practicing the present invention, as illustrated in Fig. 1, contemplates a continuous operation, the blood treatment pursuant to the invention can be effected by batched techniques.
~' .
. "
. ~
18.
llS.~333~
Thus for example a distinct, fixed quantity of blood may initially be withdrawn from the subject. Such quantity or batch, may already have present therein the desired quantities of dissolved psoralen, i.e. by prior administration to the patient; or the said psoralen may be admixed externally with the withdrawn blood. The said blood batch bearing the psoralen - may then be provided to an irradiation station, where the de-sired quantity of WA energy is rendered incident upon same.
During this process the batch of blood can be flowed through the station as previously discussed, or if the quantity of blood - is appropriate and the blood treatment chamber 28 of appropriate dimensions, the batch can simply be treated under static con-ditions until the desired energy has been dissipated. There-after, the treated blood is taken from the irradiation station, and either centrifuged as above discussed, or directly returned to the subject.
The following additional chemical agents are known to intereact with intact cells following exposure to UVA and visible : light. These agents may also be used in the system of this inven-~ 20 tion.
1. Ethidium and acridines (Yielding K.L. and - Yielding L.W.: Photoaffinity labeling of DNA. Annals of N.Y.
Acad. Sci. 346:368-378, 1980). --Also adriamycin, daunomycin, rubidazone.
2. Sulfonamides, sulfonylureas, phenothiazines, ''~
~,.......... . .
.""' , . .
' 19 .
:llS~3.3~
tetracyclines, coal tar derivatives, anthracene, pyridine, phenanthrene (Kornhauser A: Molecular aspects of phototoxicity.
Annals of N.Y. Acad. Sci. 346:398-414, 1980).
:~ OCH3 and 4, 5', 8-trimethylpsoralen, which has the structure:
~: 15 . ~
CH3 ~ 0 ~ 0 ~ 0 : CH3 .. As aforementioned, the reactive sites of the nucleic : acids are considered to be the pyrimidine bases, and it is believed that the photoinduced reaction of the present invention . involves the activated psoralen and one or more of the , 25 pyrimidine bases normally present in nucleic acids, such as ;.~, . .
~`
..
~i ; .~
.,,,~ .
.
.: , .
~lS.~3~4 thymine, cytosine, uracil or so forth. A C4 cyclo-addition takes place; the pyrimidine bases always react with their 5, 6 double bond, while the psoralens can react with either their 3, 4 double bond or with their 4', 5' double bond. In consequence two S types of photo-adducts can be obtained. This ability to bond ; at two regions of the linear psoralen structure enables the said structure upon photo-activation to link to one pyrimidine base, or to two pyrimidine bases which engage both of the reactive double bonds of the psoralen structure. Where this double linking occurs, cross-linking can be effected between the two strands of DNA, which is particularly effective in inhibiting the metabolic ; functions of the associated nucleated cells, such as the lympho-cytes.-Brief Description of Drawings The invention is diagrammatically illustrated, by way of example, in the drawings appended hereto, in which:
Fig. 1 is a schematic flow diagram illustrating a preferred embodiment of a system operating in accordance with the present invention;
Fig. 2 is a schematic elevational view of the irradia-tion station portion of the Fig. 1 system;
Fig. 3 is a plan view, schematic in nature, of one embodiment of the irradiation station of Fig. 2; and Figs. 4 and 5 are cross-sectional views, taken along the lines 4-4 and 5-5 of ~ig. 3, and illustrate the configura-'' . . .
. .
.
;,',"
.
,,; ~
10 .
~15~?,,3:~4 tions of the flow passageway and the output passage for the Fig. 3 device.
Description of Preferred Embodiment In Fig. 1 herein a schematic diagram appears of a system 10 in accordance with the present invention. Except for the irradiation station, the bulk of the components of system 10 are per se conventional and known in the art; and hence it is not deemed appropriate or necessary to vastly detail same.
As indicated in the Figure, blood may initially be withdrawn from the human subject, as at 12. Typically the ` blood is withdrawn via a donor needle, which may e.g. be emplaced at the right antecubital vein. In the showing of Fig. 1, it is assumed that the processing of blood pursuant to the invention is conducted on a continuous basis, i.e. for purposes of the present discussion the flow may be regarded as continuous from withdrawal at 12, to final return of the blood to the subject at 14. Such return 14 is typically effected via a recipient needle positioned in the left antecubital vein. Where the flow is indeed continuous in this manner, a typical blood flow -20 1 utilizable in practice of the invention is in range of from about j 10 to 75 ml/min, with a more preferred range being from about 40 to 50 ml/min. The indicated flow rates are effected by means of a pump 16, which is positioned in the extracorporeal blood flow - stream generally indicated at 18, and may comprise one of numerous , 25 types of pumps used for blood flow treatment purposes, including .
.~ ~
lS~4 such pumps as those available from Haemonetics Corp. under Model Designation 30.
As is known in the pertinent medical art, anti-coagu-lants are preferably injected into the extracorporeal blood flow stream at 20, i.e. close to the point of blood withdrawal.
Such anti-coagulants can comprise solutions of acid citrate dextrose and/or of heparin, or of other known compositions useful - for this purpose.
An occluded vein sensor 22 is preferably provided in stream 18 for purposes, as known in the art. Such sensor basically comprises a reservoir or buffer volume, the object of which is to prevent or inhibit generation or continued existence of bubbles in the blood flow stream.
Pursuant to a preferred mode of practicing the present invention, the photoactive psoralen is preferably added to the blood of the human subject external to such subject; and thus ,~ as sho~n in the system 10 of Fig. 1, may be provided to the flowing blood downstream of pump 16, and just upstream of where the blood enters the irradiation station 24.
As has been discussed under the "Summary of Invention", the preferred psoralen for use in the process of the invention is 8-methoxypsoralen (8-MOP). As also discussed, other photoactive ; psoralens as previously described, are also utilizable in the method of the invention. The basic technique used in introducing the psoralen, is to dissolve same in an isotonic solution, which ~, :- .
.
'' .
.
l~S;~
thereafter is directly injected into the flowing blood streams, as at 26. The psoralen is injected at a rate in comparison to the blood flow rate, as to achieve a concentration in the blood thereafter passed to irradiation station 24, of from about 1 nano-gram to 100 micrograms of dissolved psoralen per ml of blood.
In the foregoing connection it should be appreciated that the primary objective of the operations thus far described - is one of achieving the desired dissolved concentration of the photoactive psoralen prior to introduction of the blood to ; 10 the irradiation station. In accordance with a further aspect of the invention, it will therefore be appreciated that the said photoactive compound need not necessarily be directly introduced by injection into the extracorporeal blood stream 18 flowing in Fig. 1. RaLher, it is also acceptable to achieve the desired psoralen concentration levels by orally or otherwise administer-ing the compound directly to the patient.
,~ Indeed, in those instances of the prior art which have . .~.
been heretofore discussed, wherein 8-MOP has been utilized in treatment of psoriasis, it has been usual for the psoralen to ~": . .
be orally administered. Where, pursuant to the invention, the i psoralen is thus orally administered, it can be provided in oral dosages of from about .6 to 1.0 mg per kg of body weight.
~.
The desired concentration range in the blood used for practice of the invention, is then achieved in about two hours from oral administration.
'' .. ~
.
.~ ~
l~S;~3~
a However, it is preferred to introduce the psoralen to the extracorporeal stream (or to an extracorporeal batch volume) in order to achieve more exact concentration levels;
and further, to avoid or minimize possible side effects and the like, which can occur from administration of any drug directly to the body system.
At irradiation station 24, consisting of an irradiation chamber 28 and radiation source 30, the blood now carrying in solution the desired psoralen concentration, is subjected to ultraviolet radiation in the WA portion of the spectrum.
10, Such WA portion of the spectrum includes primarily wave lengths in the range from about 3200 to 4600 Angstroms. For present purposes it is preferred to use a radiation source having the bulk of its spectral components in the 3200 to 4000 Angstrom range, with peak intensities at about 3600 to 3700 Angstroms.
", 15 ,~ Such radiation passes readily through conventional clear plastic ;; tubing.
-' In Fig. 2, a schematic elevational view appears of ~; an irradiation station 24 of a type suitable for use with the ~ invention. Such station consists of a blood treatment or ;; -20 -,~ irradiation chamber 28, having an inlet 31 and an outlet 32, enabling blood flow through the chamber, and a spaced source 30 of WA
radiation. The chamber 28 can take various forms, with the principle requirement for same being that the wall 34 of same opposed to source 30, be substantially transparent to the incident WA radiation. The said chamber (or at least wall 34) :,., .~
,i,,, ' ' , ~ , . . :
:
~1S,~ 3~
can therefore typically be comprised of various substantially WA-transparent plastics, as are commonly used in tubing con-structed for administration of standard intrav~nous solutions, such as polyvinyl chloride and the like.
In one embodiment of chamber 28, the said device can comprise a simple envelope, i.e., the central void 36 is substantially of thin rectangular cross-section. Where, how-..;
ever, the blood is to be treated as preferred, on a continuous basis, superior flow characteristics and better control of the exposure time can be achieved where blood treatment chamber 28 has a configuration as shown in Figs. 3, 4 and 5. In this instance a tubular coil 38, which in cross-section (Fig. 5) is ,~~ flattened to a very elongated elipse, is fixedly maintained in or upon a support plate 40. The blood flow inlet 30 to the coil is of circular cross section, and in terms of Fig. l is at a .....
point downstream of pump 16. The feed-in for the psoralen com-pound is schematically depicted at 26. The highly flattened ~; cross-section of the coil enables good flow for the blood passing through the coil, but more importantly, enables good exposure of the flowing blood to the incident WA radiation. The ; outlet 32 is again returned to a circular cross-section.
' WA source 30 may comprise one or a plurality of side-by-side or otherwise arranged WA light sources 41, each of which may be backed by a reflector 42. The ~VA sources can ~ 25 comprise commercially available lamps, numerous types of which '~
~ . .
. ~
.~ ~
15.
~l~s;~3~
:`
are known in the art.
By way of example, source 30 can comprise a single 1000 watt Hg lamp of the type available from Oriel Corporation `~ of Stamford, Connecticut, under Model designation 6287. When used with appropriate filters this source provides a good relatively contiuous spectrum of high intensity radiation between 3200 and 4000 Angstroms, with a peak emission at about 3650 Angstroms. The said lamp with a suitable reflector can be positioned approximately 5 to 30 cm from chamber 28.
With the flow rates utilized in accordance with one aspect of the invention, such a source will provide absorbed energy in the flowing blood within the range of interest for practicing the method of the invention.
The blood flow from irradiation station 24 proceeding as shown in Fig. 1 via outlet 32, can be directly returned to -:, the subject at 14. Under these circumstances, the modified lymphocyes, i.e. wherein bonding of nucleic acid to the . ., ~: photo-activated psoralen compounds has been effected, are impaired in their metabolic processes, in consequence of which : 20 the said lymphocytes will be rapidly broken down and destroyed by normal processes occuring in the subject. Since further, and as already discussed, ~he metabolic processes in the abnormal lymphocytes associated with disease conditions are usually ~-~ accelerated, the breakdown in functioning, and the destruction of such abnormal lymphocytes, is accelerated beyond the cor-. .
. ~ t .. . ' .
16.
`;`
responding effects on rate of normal lymphocytes, thereby con-tributing to the destruction of the abnormal lymphocyte population in the blood supply of the subject.
; The burden placed upon the body's organ system, how-S ever, can be further alleviated, by utilizing in conjunction with the present system, a continuous centrifuge 44, which , device serves several functions.
It is to be noted that continuous centrifuges of the type here utilized, have been long employed in blood flow processing systems commercially available from several manu-;: acturers, including Haemonetics Corporation of`Braintree, Massachusetts, and the IBM Corporation, Medical Products Division, ~; of Monsey, New York. In the prior art systems in which such de-vices have been utilized all elements of Fig. 1 have been present, with the singularly important exception of the irradiation station ^- 24. The function of the continuous centrifuge in such prior art systems has been one of separating excess lymphocytes or other , blood components of interest. Where so used, a detriment of such system was the inefficiency of same, i.e. the centrifuging process i` 20 can at best remove about 40 to 50% of the lymphocytes, and unfor-v tunately also removes numerous components which are in fact desired to be retained.
In the system 10 of the present invention, two functions :, can be performed by the continuous centrifuge 44. One of ' 25 these, is removal of lymphocytes, as previously discussed.
''' ' '' .
.
~533;~4 Because the present invention, however, relies primarily on impairment of function of the lymphocytes to ultimately re-duce the functioning population of same, the centrifuge 44 need not be relied upon to the extent that same has been in . 5 the aforementioned prior art arrangements. From a mechanical viewpoint, this implies that one need not work as close to the specific gravity interface between the lymphocyte fraction of the blood and the desirable fractions of the blood which ....
, one seeks to retain. Thus one can avoid undue separation of those desired fractions of the whole blood.
,, .~. i The continuous centrifuge 44, may further be utilized for an additional important purpose. In particular, some or ~r~, virtually all of the blood plasma may be removed at 46 and ,,;
replaced with fresh plasma at 48. This washing technique ~ 15 enables one to effectively withdraw the excess psoralen compounds which may be presented in the blood plasma, replacing the plasma !, at 46 with psoralen-free isotonic fluid. Thus, when the blood is returned to the subject at 14, it is substantially free of any excess psoralens, i.e. other than those which have combined -20 with the nucleic acid components of the lymphocytes in the manner desired.
It should also be reemphasized that while the preferred mode of practicing the present invention, as illustrated in Fig. 1, contemplates a continuous operation, the blood treatment pursuant to the invention can be effected by batched techniques.
~' .
. "
. ~
18.
llS.~333~
Thus for example a distinct, fixed quantity of blood may initially be withdrawn from the subject. Such quantity or batch, may already have present therein the desired quantities of dissolved psoralen, i.e. by prior administration to the patient; or the said psoralen may be admixed externally with the withdrawn blood. The said blood batch bearing the psoralen - may then be provided to an irradiation station, where the de-sired quantity of WA energy is rendered incident upon same.
During this process the batch of blood can be flowed through the station as previously discussed, or if the quantity of blood - is appropriate and the blood treatment chamber 28 of appropriate dimensions, the batch can simply be treated under static con-ditions until the desired energy has been dissipated. There-after, the treated blood is taken from the irradiation station, and either centrifuged as above discussed, or directly returned to the subject.
The following additional chemical agents are known to intereact with intact cells following exposure to UVA and visible : light. These agents may also be used in the system of this inven-~ 20 tion.
1. Ethidium and acridines (Yielding K.L. and - Yielding L.W.: Photoaffinity labeling of DNA. Annals of N.Y.
Acad. Sci. 346:368-378, 1980). --Also adriamycin, daunomycin, rubidazone.
2. Sulfonamides, sulfonylureas, phenothiazines, ''~
~,.......... . .
.""' , . .
' 19 .
:llS~3.3~
tetracyclines, coal tar derivatives, anthracene, pyridine, phenanthrene (Kornhauser A: Molecular aspects of phototoxicity.
Annals of N.Y. Acad. Sci. 346:398-414, 1980).
3. Specifically reactive antibodies (Richard F.F. and Lifter J.: Photoaffinity probes in the antibody combinbing region. Annals of N.Y. Acad. Sci. 346:78-89, 1980).
While the present invention has been particularly described in terms of specific embodiments thereof, it will be understood in view of the present disclosure, that numerous variations upon the invention are now enabled to those skilled in the art, which variations yet reside within the scope of the present invention. Accordingly, the invention is to be broadly construed, and limited only by the scope and spirit of ~; the claims now appended hereto.
.
~ 25 . :
d
While the present invention has been particularly described in terms of specific embodiments thereof, it will be understood in view of the present disclosure, that numerous variations upon the invention are now enabled to those skilled in the art, which variations yet reside within the scope of the present invention. Accordingly, the invention is to be broadly construed, and limited only by the scope and spirit of ~; the claims now appended hereto.
.
~ 25 . :
d
Claims (9)
1. A system for use in treating human blood to re-duce the functioning lymphocyte population of same, comprising:
means for irradiating portions of the said blood supply externally to the body of said subject with UV radiation in the presence of from about 1 nanogram to 100 micrograms per ml of blood of a dissolved psoralen which is capable upon activa-tion by said UV radiation of forming photoadducts with DNA, to thereby effect chemical bonding between said psoralen and the nucleic acid of said lymphocytes, thereby altering the said nucleic acid and inhibiting the metabolic processes of said lymphocytes.
means for irradiating portions of the said blood supply externally to the body of said subject with UV radiation in the presence of from about 1 nanogram to 100 micrograms per ml of blood of a dissolved psoralen which is capable upon activa-tion by said UV radiation of forming photoadducts with DNA, to thereby effect chemical bonding between said psoralen and the nucleic acid of said lymphocytes, thereby altering the said nucleic acid and inhibiting the metabolic processes of said lymphocytes.
2. A system in accordance with claim 1, wherein said means for irradiating portions of said blood comprises an irradiation station which comprises a blood treatment chamber and a spaced source of UVA radiation, at least the surface of said treatment station abounding the blood and opposed to said radiation source being substantially transparent to activating UVA radiation.
3. A system in accordance with claim 2, further including means to continuously flow blood withdrawn from said subject through said irradiation station, and return said blood to said subject following irradiation.
4. A system in accordance with claim 3, further including in line with the flow from said irradiation station, con-tinuous centrifuge means for removing excess lymphocytes, and for removing and replacing plasma components of said blood, to thereby remove excess psoralen compounds before returning said blood to said subject.
5. A system for treating blood from a patient with a photoactive chemical which comprises a source of UV radiation;
a blood treatment chamber adapted to receive radiation from said source;
continuous transport means adapted to trans-port blood from a patient, through said blood treatment chamber and back to said patient.
a blood treatment chamber adapted to receive radiation from said source;
continuous transport means adapted to trans-port blood from a patient, through said blood treatment chamber and back to said patient.
6. The system of claim 5 wherein said chamber com-prises a conduit for the passage of blood, said conduit being constructed of a material substantially transparent to activating UV radiation.
7. The system of claim 6 wherein said conduit forms a tortuous pathway through said chamber in a manner adapted to provide an adequate residence time for blood in said chamber to be exposed to UV radiation.
8. The system of claim 5 wherein said transport means comprises means to inject a UV sensitive chemical into the blood prior to passage of the blood through said treatment chamber.
9. A system in accordance with claim 5, further in cluding in line with the flow from said blood treatment chamber, a centrifuge means for separation of the components of the blood.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/102,553 US4321919A (en) | 1979-12-11 | 1979-12-11 | Method and system for externally treating human blood |
US102,553 | 1987-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1153334A true CA1153334A (en) | 1983-09-06 |
Family
ID=22290431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000366516A Expired CA1153334A (en) | 1979-12-11 | 1980-12-10 | System for externally treating human blood |
Country Status (13)
Country | Link |
---|---|
US (1) | US4321919A (en) |
EP (1) | EP0030358B1 (en) |
JP (1) | JPS5930683B2 (en) |
AT (1) | ATE12352T1 (en) |
AU (1) | AU546122B2 (en) |
BR (1) | BR8008053A (en) |
CA (1) | CA1153334A (en) |
DE (1) | DE3070398D1 (en) |
DK (1) | DK520080A (en) |
ES (1) | ES497578A0 (en) |
IL (1) | IL61658A0 (en) |
NO (1) | NO803706L (en) |
ZA (1) | ZA807529B (en) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4398906A (en) * | 1979-12-11 | 1983-08-16 | Frederic A. Bourke, Jr. | Method for externally treating the blood |
US4612007A (en) * | 1981-06-16 | 1986-09-16 | Edelson Richard Leslie | Method and system for externally treating the blood |
US4613322A (en) * | 1982-12-08 | 1986-09-23 | Edelson Richard Leslie | Method and system for externally treating the blood |
US4684521A (en) * | 1982-12-08 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
US4683889A (en) * | 1983-03-29 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
DE3483751D1 (en) * | 1983-05-02 | 1991-01-31 | Diamond Scient Co | PHOTOCHEMICAL DISABLING TREATMENT OF FULL BLOOD OR BLOOD COMPONENTS. |
US5176921A (en) * | 1983-05-02 | 1993-01-05 | Diamond Scientific Co. | Method of blood component decontamination by glucose addition |
US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4727027A (en) * | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
WO1985000954A1 (en) * | 1983-09-01 | 1985-03-14 | The Trustees Of Columbia University In The City Of | Processes for development of acceptance of transplanted organs and tissues |
US4861704A (en) * | 1983-09-01 | 1989-08-29 | The Trustees Of Columbia University In The City Of New York | Processes for development of acceptance of transplanted organs and tissues |
US4946438A (en) * | 1983-09-01 | 1990-08-07 | The Trustees Of Columbia University In The City Of New York | Process for development of acceptance of transplanted organs and tissues |
CA1253115A (en) * | 1983-09-29 | 1989-04-25 | Extracorporeal Medical Specialties, Inc. | Apparatus and methods for treating cells with radiation |
US4573960A (en) * | 1984-10-29 | 1986-03-04 | Extracorporeal Medical Specialties, Inc. | Three phase irradiation treatment process |
US4681568A (en) | 1984-10-29 | 1987-07-21 | Mcneilab, Inc. | Valve apparatus for photoactivation patient treatment system |
US4708715A (en) * | 1984-10-29 | 1987-11-24 | Mcneilab, Inc. | Light array assembly for photoactivation patient treatment system |
US4568328A (en) * | 1984-10-29 | 1986-02-04 | Extracorporeal Medical Specialties, Inc. | Automated photophoresis blood portion control methods and apparatus |
US4608255A (en) * | 1985-01-31 | 1986-08-26 | American National Red Cross | Biocompatible method for in situ production of functional platelets and product produced thereby lacking immunogenicity |
JPS61153487U (en) * | 1985-03-12 | 1986-09-22 | ||
US4998931A (en) * | 1985-07-05 | 1991-03-12 | Puget Sound Blood Center | Method of reducing immunogenicity and inducing immunologic tolerance |
US4775625A (en) * | 1986-11-21 | 1988-10-04 | The Medical College Of Wisconsin, Inc. | Inactivating enveloped viruses with a merocyanine dye |
US5039483A (en) * | 1987-03-10 | 1991-08-13 | The Medical College Of Wisconsin, Inc. | Antiprotozoan method |
US5304113A (en) * | 1986-11-21 | 1994-04-19 | The Mcw Research Foundation, Inc. | Method of eradicating infectious biological contaminants |
US4915683A (en) * | 1986-11-21 | 1990-04-10 | The Medical College Of Wisconsin, Inc. | Antiviral method, agents and apparatus |
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
IL92996A (en) * | 1989-01-10 | 1996-06-18 | Bisaccia Emil | Photoactive compounds as medicaments for the treatment of virus infections and method for production of vaccines |
US4960408A (en) * | 1989-01-10 | 1990-10-02 | Klainer Albert S | Treatment methods and vaccines for stimulating an immunological response against retroviruses |
US5284869A (en) * | 1991-12-17 | 1994-02-08 | Emil Bisaccia | Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty |
US4921473A (en) * | 1989-02-02 | 1990-05-01 | Therakos, Inc. | Multicomponent fluid separation and irradiation system |
US4999375A (en) * | 1989-04-11 | 1991-03-12 | Hoffmann-La Roche Inc. | Psoralen reagent compositions for extracorporeal treatment of blood |
US5503721A (en) | 1991-07-18 | 1996-04-02 | Hri Research, Inc. | Method for photoactivation |
DE4005704A1 (en) * | 1990-02-23 | 1991-08-29 | Amelung Doris | METHOD FOR TREATING BLOOD BY OXYGEN AND LIGHT, AND DEVICE FOR CARRYING OUT THIS METHOD |
US6187572B1 (en) | 1990-04-16 | 2001-02-13 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
US5418130A (en) * | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
DE69117940T2 (en) * | 1990-12-20 | 1996-11-21 | Baxter Int | DEVICE AND METHOD FOR REMOVING IMPURITIES FROM LIQUIDS |
ZA919934B (en) * | 1990-12-20 | 1992-09-30 | Baxter Int | Systems and methods for eradicating contaminants using photoactive materials in fluids like blood using discrete sources of radiation |
DE69131797T2 (en) * | 1990-12-20 | 2000-06-29 | Baxter Int | SYSTEMS AND METHODS FOR THE SIMULTANEOUS REMOVAL OF FREE AND TIED IMPURITIES FROM LIQUIDS, LIKE BLOOD, WITH THE AID OF PHOTOACTIVE THERAPY AND CELL SEPARATION TECHNIQUES |
WO1992011060A1 (en) * | 1990-12-20 | 1992-07-09 | Baxter International Inc. | Systems for eradicating contaminants in fluids |
US5116864A (en) * | 1991-04-09 | 1992-05-26 | Indiana University Foundation | Method for preventing restenosis following reconfiguration of body vessels |
US5263925A (en) * | 1991-07-22 | 1993-11-23 | Gilmore Jr Thomas F | Photopheresis blood treatment |
US5219882A (en) * | 1991-10-24 | 1993-06-15 | Emil Bisaccia | Treatment methods for lymes disease and associated debilitating conditions |
US6433343B1 (en) | 1992-03-02 | 2002-08-13 | Cerus Corporation | Device and method for photoactivation |
US5288605A (en) * | 1992-03-02 | 1994-02-22 | Steritech, Inc. | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen |
DE69328685T2 (en) * | 1992-08-07 | 2000-11-23 | Cerus Corp | METHOD FOR INACTIVATING BACTERIA IN BLOOD PREPARATIONS WITH THE HELP OF METHOXYPSORALS |
US5651993A (en) | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
DE4317600C2 (en) * | 1993-05-27 | 1995-07-13 | Ulrich Heinrich C | Compression apparatus for creating an artificial void on the extremities |
US6420570B1 (en) | 1993-06-28 | 2002-07-16 | Cerus Corporation | Psoralen compounds |
US5399719A (en) | 1993-06-28 | 1995-03-21 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
US5625079A (en) | 1993-06-28 | 1997-04-29 | Cerus Corporation | Synthesizing psoralen compounds useful as intermediates |
US5527704A (en) | 1994-12-06 | 1996-06-18 | Baxter International Inc. | Apparatus and method for inactivating viral contaminants in body fluids |
US5669396A (en) * | 1996-01-16 | 1997-09-23 | President And Fellows Of Harvard College | Methods of detecting and treating vaso-occlusive crisis in sickle cell disease |
CA2250919C (en) * | 1996-03-29 | 2008-05-13 | Therakos, Inc. | Photopheresis treatment of leukocytes |
ES2251020T3 (en) * | 1996-03-29 | 2006-04-16 | Therakos, Inc. | TREATMENT FOR CHRONIC HCV INFECTION PHOTOPHERESIS. |
US6228995B1 (en) | 1996-04-09 | 2001-05-08 | Therakos, Inc. | Method for removal of psoralens from biological fluids |
DE69737219T2 (en) | 1996-11-22 | 2007-11-08 | Therakos, Inc. | Apparatus with stirring device for irradiating a blood product |
US5951509A (en) * | 1996-11-22 | 1999-09-14 | Therakos, Inc. | Blood product irradiation device incorporating agitation |
DK0994743T3 (en) | 1997-07-10 | 2006-10-02 | Therakos Inc | Treatment of inflammatory disorders of the intestine or bladder |
EP1032265B1 (en) * | 1997-11-20 | 2003-10-29 | Cerus Corporation | New psoralens for pathogen inactivation |
US20070099170A1 (en) * | 1998-07-21 | 2007-05-03 | Navigant Biotechnologies, Inc. | Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate |
US7049110B2 (en) * | 1998-07-21 | 2006-05-23 | Gambro, Inc. | Inactivation of West Nile virus and malaria using photosensitizers |
US7498156B2 (en) * | 1998-07-21 | 2009-03-03 | Caridianbct Biotechnologies, Llc | Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components |
US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
US20030215784A1 (en) * | 1998-07-21 | 2003-11-20 | Dumont Larry Joe | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US6113566A (en) * | 1998-12-15 | 2000-09-05 | Foundation For Blood Irradiation Inc. | Ultraviolet blood irradiation method and apparatus |
US7109031B2 (en) * | 1999-04-20 | 2006-09-19 | Yale University | Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
CA2368855C (en) | 1999-04-20 | 2012-05-29 | Richard Leslie Edelson | Differentiation of monocytes into functional dendritic cells |
US20050158856A1 (en) * | 1999-04-20 | 2005-07-21 | Edelson Richard L. | Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials |
US20050084966A1 (en) * | 1999-04-20 | 2005-04-21 | Edelson Richard L. | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
US6219584B1 (en) | 1999-07-09 | 2001-04-17 | Therakos, Inc. | Method and system for determining an effective amount of light energy to delivery to fluids having targets for the light energy |
US7094378B1 (en) | 2000-06-15 | 2006-08-22 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US7220747B2 (en) | 1999-07-20 | 2007-05-22 | Gambro, Inc. | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer |
US6495366B1 (en) * | 1999-09-03 | 2002-12-17 | Therakos, Inc. | Uninterrupted flow pump apparatus and method |
US8722422B2 (en) | 1999-09-03 | 2014-05-13 | Therakos, Inc. | Uninterrupted flow pump apparatus and method |
US6719715B2 (en) * | 1999-09-16 | 2004-04-13 | Vasogen Ireland Limited | Apparatus and process for conditioning organic fluid |
EP1267931B1 (en) * | 1999-10-05 | 2004-12-29 | Universite De Montreal | Rhodamine derivatives for photodynamic diagnosis and treatment |
US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
US6793643B1 (en) | 2000-04-21 | 2004-09-21 | Therakos, Inc. | Low extracorporeal volume treatment system |
US7985588B2 (en) * | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
US7648699B2 (en) * | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
TW590780B (en) * | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
US6843961B2 (en) * | 2000-06-15 | 2005-01-18 | Gambro, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
JP4116429B2 (en) * | 2000-11-13 | 2008-07-09 | バイエル アクチェンゲゼルシャフト | Method for inactivating microorganisms in fluids using ultraviolet radiation |
WO2003045979A2 (en) * | 2001-11-29 | 2003-06-05 | Therakos, Inc. | Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells |
US7479123B2 (en) * | 2002-03-04 | 2009-01-20 | Therakos, Inc. | Method for collecting a desired blood component and performing a photopheresis treatment |
US7211037B2 (en) * | 2002-03-04 | 2007-05-01 | Therakos, Inc. | Apparatus for the continuous separation of biological fluids into components and method of using same |
US7186230B2 (en) | 2002-03-04 | 2007-03-06 | Therakos, Inc | Method and apparatus for the continuous separation of biological fluids into components |
US20040127840A1 (en) * | 2002-03-04 | 2004-07-01 | Steve Gara | Blood separation apparatus and method of using the same |
CA2482021C (en) * | 2002-04-24 | 2007-06-19 | Gambro, Inc. | Removal of adenine during a process of pathogen reducing blood and blood components |
US20090023130A1 (en) * | 2003-02-28 | 2009-01-22 | Caridianbct Biotechnologies, Llc | Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light |
US20050080373A1 (en) * | 2003-10-09 | 2005-04-14 | Xiaoling Wang | Apparatus and a method for treating blood related illnesses |
AU2004237844B2 (en) | 2003-12-23 | 2011-01-27 | Therakos, Inc. | Extracorporeal photopheresis in combination with anti-TNF treatment |
US7087177B2 (en) * | 2004-04-16 | 2006-08-08 | Baxter International Inc. | Methods for determining flow rates of biological fluids |
US8057785B2 (en) * | 2004-12-22 | 2011-11-15 | Omj Ireland Limited | Phototherapy compositions and methods |
US9169461B2 (en) | 2005-11-02 | 2015-10-27 | Therakos, Inc. | Use of apoptotic cells ex vivo to generate regulatory T cells |
EP2527458A3 (en) | 2006-05-02 | 2012-12-26 | Therakos, Inc. | Methods and reagents for detecting susceptilbility to graft versus host disease |
ITVE20070005A1 (en) * | 2007-01-25 | 2008-07-26 | Associazione Veneta Per La Lotta Alla Talassemia | DRUG FOR THE TREATMENT OF TALASSEMIA, FALCIFORM ANEMIA AND ALL THE OTHER FORMS OF ANEMIA TREATABLE WITH THIS, DRUG ACTIVATION METHOD, PHARMACEUTICAL COMPOSITION AS AN ACTIVE PRINCIPLE THE DRUG AND PHOTOCHEMIOTHERAPY METHOD U |
WO2008108980A2 (en) * | 2007-03-01 | 2008-09-12 | Nanospectra Biosciences, Inc. | Devices and methods for extracorporeal ablation of circulating cells |
AU2008282232A1 (en) * | 2007-08-01 | 2009-02-05 | Terumo Bct Biotechnologies, Llc. | Pathogen inactivation of whole blood |
KR101609224B1 (en) * | 2011-01-24 | 2016-04-05 | 다카라 바이오 가부시키가이샤 | Method for modifying nucleic acids |
US9399093B2 (en) * | 2012-01-27 | 2016-07-26 | Fenwal, Inc. | Systems and methods for performing online extracorporeal photopheresis |
US11678825B2 (en) | 2018-10-04 | 2023-06-20 | Fenwal, Inc. | Methods and systems for collecting samples in a photopheresis procedure |
US11883543B2 (en) | 2019-04-16 | 2024-01-30 | Fenwal, Inc. | Systems and methods for photoactivation of a biological fluid |
KR102252218B1 (en) * | 2019-11-01 | 2021-05-14 | 김진왕 | Eco-Friendly Smart Blood Modulation Device |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1683877A (en) * | 1927-03-03 | 1928-09-11 | Lester A Edblom | Means for treating blood-stream infections |
FR975851A (en) * | 1948-12-04 | 1951-03-12 | Apparatus for irradiating the blood of a patient by ultraviolet rays | |
US3325641A (en) * | 1964-02-17 | 1967-06-13 | George W Jones | Apparatus for treating a thin film of liquid by exposure to radiant energy |
US3788319A (en) * | 1971-07-30 | 1974-01-29 | Univ Iowa State Res Found Inc | System for exchanging blood ultrafiltrate |
FR2426473A1 (en) * | 1978-05-26 | 1979-12-21 | Carraz Gilbert | Treatment of leukaemia by UV irradiation of blood - in presence of a phenothiazine amine as radiation sensitiser |
-
1979
- 1979-12-11 US US06/102,553 patent/US4321919A/en not_active Expired - Lifetime
-
1980
- 1980-12-02 ZA ZA00807529A patent/ZA807529B/en unknown
- 1980-12-03 DE DE8080107540T patent/DE3070398D1/en not_active Expired
- 1980-12-03 EP EP80107540A patent/EP0030358B1/en not_active Expired
- 1980-12-03 AT AT80107540T patent/ATE12352T1/en not_active IP Right Cessation
- 1980-12-05 DK DK520080A patent/DK520080A/en unknown
- 1980-12-08 AU AU65171/80A patent/AU546122B2/en not_active Expired
- 1980-12-08 IL IL61658A patent/IL61658A0/en unknown
- 1980-12-09 NO NO803706A patent/NO803706L/en unknown
- 1980-12-10 BR BR8008053A patent/BR8008053A/en not_active IP Right Cessation
- 1980-12-10 CA CA000366516A patent/CA1153334A/en not_active Expired
- 1980-12-10 ES ES497578A patent/ES497578A0/en active Granted
- 1980-12-11 JP JP55175203A patent/JPS5930683B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
EP0030358B1 (en) | 1985-03-27 |
IL61658A0 (en) | 1981-01-30 |
AU546122B2 (en) | 1985-08-15 |
ATE12352T1 (en) | 1985-04-15 |
JPS5930683B2 (en) | 1984-07-28 |
ES8202484A1 (en) | 1982-02-01 |
US4321919A (en) | 1982-03-30 |
AU6517180A (en) | 1981-06-18 |
JPS56131520A (en) | 1981-10-15 |
BR8008053A (en) | 1981-06-23 |
DE3070398D1 (en) | 1985-05-02 |
DK520080A (en) | 1981-06-12 |
NO803706L (en) | 1981-06-12 |
EP0030358A2 (en) | 1981-06-17 |
EP0030358A3 (en) | 1982-03-24 |
ES497578A0 (en) | 1982-02-01 |
ZA807529B (en) | 1981-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1153334A (en) | System for externally treating human blood | |
US4464166A (en) | Method for externally treating the blood | |
US4398906A (en) | Method for externally treating the blood | |
US4428744A (en) | Method and system for externally treating the blood | |
US4683889A (en) | Method and system for externally treating the blood | |
US4613322A (en) | Method and system for externally treating the blood | |
US4612007A (en) | Method and system for externally treating the blood | |
US4684521A (en) | Method and system for externally treating the blood | |
US4950225A (en) | Method for extracorporeal blood shear treatment | |
US5104373A (en) | Method and apparatus for extracorporeal blood treatment | |
US5628727A (en) | Extracorporeal virioncidal apparatus | |
CA1176165A (en) | Method and system for externally treating the blood | |
US5571082A (en) | Method of producing therapeutic effect upon an organism to reduce the pathologic lymphocyte population | |
KR101147625B1 (en) | Irradiation chamber | |
RU2152788C1 (en) | Method of extracorporal immunocorrection in children with suppurative-septic diseases | |
RU2076743C1 (en) | Method for performing plasmophoresis treatment | |
Karandashov et al. | Changes in rheological properties of the blood after irradiation with helium-neon laser | |
SU1361757A1 (en) | Method of preparing leukocytes from blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |